Expression of JNK-interacting protein JIP-1 and insulin-like growth factor II in Wilms tumour cell lines and primary Wilms tumours

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2467-2472

  Engström, Wilhelm ^a   Granerus, Marika ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

IGF II; JIP 1; Wilms tumours

Indexed keywords

SOMATOMEDIN B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; JIP 1 GENE; NEPHROBLASTOMA; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MICE; PROTEIN BINDING; RECOMBINANT PROTEINS; WILMS TUMOR;

EID: 69249181357     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ward A: Beckwith Wiedemann syndrome and Wilms tumour. MoI Hum Reprod 3: 157-168, 1997.
2. Knudson A and Strong LC: Mutation and cancer. A model for Wilms tumour of the kidney. J Natl Cancer Inst 48: 313-323, 1972.
3. Call KM, Glaser T and Ito CY: Isolation and characterisation of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumour locus. Cell 60: 509-520, 1990. (Pubitemid 20060879)
4. Scott J, Cowell J, Robertson ME, Priestley LM, Wadey R, Hopkins B, Pritchard J, Bell GI, Rall LB, Graham CF and Knott TJ: Insulin-like growth factor II gene expression in Wilms tumour and embryonic tissues. Nature 317: 260-262, 1985. (Pubitemid 16246503)
5. Engström W and Heath JK: Growth factors in early embryonic development. In: Fetal and Neonatal Growth. Cockburn F (ed.). John Wiley and sons, pp. 11-32, 1987.
6. Ward A, Bierke P, Pettersson E and Engström W: Insulin-like growth factors: growth, transgenes and imprinting. Zool Sci 11: 167-174, 1994. (Pubitemid 2099931)
7. Engström W, Shokrai A, Otte K, Granerus M, Gessbo Å, Bierke P, Madej A, Sjölund M and Ward A: Transcriptional regulation and biological significance of the insulin-like growth factor II gene. Cell Prolif 31: 1-16, 1998. (Pubitemid 29034441)
8. Reynolds ML, Ward A and Graham CF: Decreased skin sensory innervation in transgenic mice overexpressing insulin-like growth factor II. Neuroscience 79: 789-797, 1997. (Pubitemid 27292675)
9. Granerus M, Johannisson A, Ekblom P and Engström W: Insulin-like growth factors I and II induce cell death in Wilms tumour cells. Mol Pathol 54: 30-35, 2001. (Pubitemid 32128425)
10. Rohbe L, Larsson M, Rising A, Grip S, Burns J and Engström W: Expression of JNK-interacting protein JIP-1 is down-regulated in liver from mouse embryos with a disrupted insulin-like growth factor II gene. In Vivo 18: 643-648, 2004. (Pubitemid 39409642)
11. Engström W, Rising A and Grip S: The JNK-interacting protein JIP-1 and insulin-like growth factor II genes are co-expressed in human embryonic tumours. Anticancer Res 25: 1075-1078, 2005. (Pubitemid 40546883)
12. Talts JF, Aufderheide E, Sorokin L, Ocklind G, Mattson R and Ekblom P: Induction of mouse tenascin expression by a human sarcomatoid Wilms tumour cell line growing in nude mice. Int J Cancer 54: 868-874, 1993. (Pubitemid 23228621)
13. Hyldahl L, Engström W and Schofield PN: Stimulatory effects of basic fibroblast growth factor on the human embryonic cornea. Development 709: 693-703, 1990. (Pubitemid 20228655)
14. Engström W, Granerus M and Sachsenmaier W: Differential gene expression of 3-hydroxy 3-methyl glutaryl coenzyme A reductase and N-myc during the synchronous nuclear cycle of Physarum polycephalum. Cell Biol Int Rep 16: 1133-1137, 1992. (Pubitemid 23022922)
15. Choi KY, Satterberg E, Lyons DM and Elion EA: Ste5 tethers multiple protein kinases in the MAP kinase cascade required for mating in S. cerevisiae. Cell 78: 499-512, 1994.
16. Marcus S, Polverino A, Barr M and Wigler M: Complexes between STE5 and components of the pheromone responsive mitogen-activated protein kinase module. Proc Natl Acad Sci USA 97: 7762-7766, 1994. (Pubitemid 24238265)
17. Elton EA: The Ste5p scaffold. J Cell Sci 114: 3967-3978, 2001.
18. Burack WR and Shaw AS: Signal transduction: hanging on a scaffold. Curr Op in Cell Biol 12: 211-216, 2000.
19. Engström W, Ward A and Moorwood K: The role of scaffold proteins in JNK signalling. Cell Prolif in press 2009.
20. Bogoyevitch MA and Court NW: Counting on mitogen activated protein kinases ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 76: 1345-1354, 2004.
21. Bogoyevitch MA: The isoform specific functions of the c-Jun N-terminal kinases (JNKs) differences revealed by gene targetting. Bioessays 28: 923-934, 2006.
22. Coulombe P and Meloche S: Atypical mitogen-activated protein kinases. Structure, regulation and function. Biochim Biophys Acta 1775: 1376-1387, 2006.
23. Zarubin T and Han J: Activation and signalling of the p38 MAP kinase pathway. Cell Res 15: 11-18, 2005. (Pubitemid 41653958)
24. Dhanasekaran DN, Kashef K, Lee CM, Xu H and Reddy EP: Scaffold proteins of MAP kinase modules. Oncogene 26: 3185-3202, 2007. (Pubitemid 46763014)
25. Dickens M, Rogers JS, Cavanagh J, Rairano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL and Davis RJ: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277: 693-696, 1997. (Pubitemid 27373916)
26. Dell G, Ward A, Shokrai A, Madej A and Engström W: Regulation of the IGF system by glucocorticoids. Zool Sci 16: 377-385, 1999.
27. Smith FM, Garfield AS and Ward A: Regulation of growth and metabolism by imprinted genes. Cytogenet Genome Res 113: 279-291, 2006.
28. Xia Z, Dickens M, Raingeaud J and Davis RJ: Opposing effects of ERK and JNK-p38 MAP-kinases on apoptosis. Science 270: 1326-1331, 1995.
29. Boldt S and Kolch W: Targetting MAPK signalling: Prometheus Fire or Pandoras Box. Curr Pharm Design 70: 1885-1905, 2004.
30. Nishina H, Vaz C, Billia P, Nghiem M, Sasaki T and de la Pompa JL: Defective liver formation and liver cell apoptosis in mice lacking the stress signalling kinase SEK1/MKK4. Development 126: 505-516, 1999. (Pubitemid 29082037)
31. Lei K and Davis RJ: JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis: Proc Natl Acad Sci USA 100: 242-2437, 2003.
32. Donovan N, Becker EB, Konishi Y and Bonni A: JNK phosphorylation and activation of BAD couples the stress activated signalling pathway to the cell death machinery. J Biol Chem 277: 40944-40949, 2002. (Pubitemid 35215682)
33. Yamamoto K, Ichijo H and Korsmeyer SJ: Bcl2 is phospho-rylated and inactivated by an ASK1/JUN N-terminal kinase pathway normally activated at G2/M. MoI Cell Biol 79: 8469-8478, 1999. (Pubitemid 30414041)
34. Basu A and Haldar S: Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 538: 41-47, 2002. (Pubitemid 36287422)
35. Lei K, Nimnual A, Zong WX, Kennedy NJ, Flavell RA, Thompson CB and Davis RJ: The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by JNK. Mol Cell Biol 22: 4929-4942, 2002.
36. Haefliger JA, Tawadros T, Meylan L, Gurun SL, Roehrich ME, Martin D, Thorens B and Waeber G: The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic beta cells. J Cell Sci 116: 1463-1469, 2003. (Pubitemid 36527493)
37. 2 terminal kinase signalling. Diabetes 52: 2497-2502, 2004.
38. Xu S and Cobb MH: MEKK1 binds directly to the c-jun N- terminal kinases/stress-activated protein kinases. J Biol Chem 272: 32056-32060, 1997. (Pubitemid 28011874)
39. Kukekov NV, Xu Z and Greene LA: Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs. J Biol Chem 281: 15517-15524, 2006. (Pubitemid 43855144)